Selected Publications:
Haas AR, Tanyi JL, O'Hara MH, Gladney WL, Lacey SF, Torigian DA, Soulen MC, Tian L, McGarvey M, Nelson AM, Farabaugh CS, Moon E, Levine BL, Melenhorst JJ, Plesa G, June CH, Albelda SM, Beatty GL: Phase I Study of Lentiviral-Transduced Chimeric Antigen Receptor-Modified T Cells Recognizing Mesothelin in Advanced Solid Cancers. Mol Ther 27:1-11 : 2019.
Dangaj D, Bruand M, Grimm AJ, Ronet C, Barras D, Duttagupta PA, Lanitis E, Duraiswamy J, Tanyi JL, Benencia F, Conejo-Garcia J, Ramay HR, Montone KT, Powell DJ Jr, Gimotty PA, Facciabene A, Jackson DG, Weber JS, Rodig SJ, Hodi SF, Kandalaft LE, Irving M, Zhang L, Foukas P, Rusakiewicz S, Delorenzi M, Coukos G: Cooperation between Constitutive and Inducible Chemokines Enables T Cell Engraftment and Immune Attack in Solid Tumors. Cancer Cell 35(6):885-900 : 2019.
Tanyi JL, Dorigo O, Oza A, Strauss J, Pejovic T, Ghamande S, Prafull Ghatage, Villella J, Stephan Fiset, MacDonald LD, Hrytsenko O, Stanford MM, Newton RC, Leopold L, Rosu G: DPX-Survivac and intermittent low dose cyclophosphamide (CPA) with or without epacadostat (E) in the treatment of subjects with advanced recurrent epithelial ovarian cancer (DeCidE1 trial): T cell responses and tumor infiltration correlate with tumor regression. ASCO annual meeting, Chicago IL, : 2019.
Hu Z, Zhou J, Jiang J, Yuan J, Zhang Y, Wei X, Loo N, Wang Y, Pan Y, Zhang T, Zhong X, Long M, Montone KT, Tanyi JL, Fan Y, Wang TL, Shih IM, Hu X, Zhang L: Genomic characterization of genes encoding histone acetylation modulator proteins identifies therapeutic targets for cancer treatment. Nat Commun 13;10(1):733 : 2019.
Tanyi JL, George E: Personalized vaccination against ovarian cancer: what are the possibilities? Expert Rev Vaccines 17(11):955-958 : 2018.
Yuan J, Hu Z, Mahal BA, Zhao SD, Kensler KH, Pi J, Hu X, Zhang Y, Wang Y, Jiang J, Li C, Zhong X, Montone KT, Guan G, Tanyi JL, Fan Y, Xu X, Morgan MA, Long M, Zhang Y, Zhang R, Sood AK, Rebbeck TR, Dang CV, Zhang L: Integrated Analysis of Genetic Ancestry and Genomic Alterations across Cancers. Cancer Cell 8;34(4):549-560 : 2018.
Randall LM, Wenham RM, Low PS, Dowdy SC, Morgan MA, Tanyi JL: A phase 2, single-dose, open-label study to investigate the safety and efficacy of OTL 38 injection (OTL38) for intraoperative imaging during cytoreductive surgery for ovarian cancer. Society of Pelvic Surgeons Annual Meeting, Bucharest, Brasov, Romania, : 2018.
Janos L. Tanyi: Ovarian cancer Immunotherapy Oxford University Press (Chapter 8): 2018.
Lin X, Shen J, Dan Peng, He X, Xu C, Chen X, Tanyi JL, Montone K, Fan Y, Huang Q, Zhang L, Zhong X: RNA-binding protein LIN28B inhibits apoptosis through regulation of the AKT2/FOXO3A/BIM axis in ovarian cancer cells. Signal Transduct Target Ther 31;3:23 : 2018.
Ramirez L, Johnson ATC, Otto C, Tanyi JL, Piltz-Seymour J, Kwak JH, Prigg K, Kybert N, Preti G; California Lutheran University, Thousand Oaks, CA; University of Pennsylvania Department of Physics & Astronomy, Philadelphia, PA; University of Pennsylvania School of Veterinary Medicine, Philadelphia, PA; University of Pennsylvania, Philadelphia, PA; University of Pennsylvania Perelman School of Medicine, Narberth, PA; Global Spectroscopy 2, Union Beach, NJ; Symrise, Teterboro, Philadelphia, PA: Exploring ovarian cancer detection using an interdisciplinary investigation of its volatile odor signature. ASCO Annual Meeting, Chicago, IL, : 2018.